Elesclomol | 伊利司莫(STA-4783) | STA-4783 | Cuproptosis Inducer

首页 / / / / Elesclomol/伊利司莫

Elesclomol/伊利司莫 {[allProObj[0].p_purity_real_show]}

货号：A384622 同义名： 伊利司莫(STA-4783) / STA-4783

Elesclomol, an inhibitor of HSP90, is a potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells.

Elesclomol/伊利司莫化学结构
CAS号：488832-69-5

Elesclomol/伊利司莫 3D分子结构
CAS号：488832-69-5

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Elesclomol/伊利司莫纯度/质量文件产品仅供科研

货号：A384622 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: 更多 >

Elesclomol/伊利司莫生物活性

描述	Elesclomol, an inhibitor of HSP90, is a potent oxidative stress inducer that elicits pro-apoptosis events among tumor cells.

Elesclomol/伊利司莫细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源
647-V cell		Growth inhibition assay		Inhibition of human 647-V cell growth in a cell viability assay, IC50=6.9 nM	SANGER
697 cell		Growth inhibition assay		Inhibition of human 697 cell growth in a cell viability assay, IC50=6.13 nM	SANGER
A2780 cell		Growth inhibition assay		Inhibition of human A2780 cell growth in a cell viability assay, IC50=0.594 nM	SANGER
A375 cell		Growth inhibition assay		Inhibition of human A375 cell growth in a cell viability assay, IC50=4.14 nM	SANGER

Elesclomol/伊利司莫临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT00088088	Stage IIIB Non-Small Cell Lung... 展开 >> Cancer Stage IV Non-Small Cell Lung Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, Arkansas ... 展开 >> NEA Clinic Jonesboro, Arkansas, United States, 72401 United States, California Wilshire Oncology Medical Group Pamona, California, United States, 91767 St. Francis Memorial Hospital San Francisco, California, United States Cancer Institute Medical Group Santa Monica, California, United States, 90404 Kaiser Permanete Vallejo, California, United States United States, Connecticut Oncology Associates of Bridgeport Trumball, Connecticut, United States, 06611 United States, Florida ACORN Miami, Florida, United States Oncology Hematology Consultants Sarasota, Florida, United States, 34236 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 The Cancer Institute at Alexian Brothers Elk Grove Village, Illinois, United States, 60007 Ingalls Hospital Harvey, Illinois, United States, 60426 United States, Louisiana Overton Brooks, VAMC Shreveport, Louisiana, United States, 71101 LSUHSC - Shreveport Feist Weiller Cancer Center Shreveport, Louisiana, United States, 71130 United States, Maryland Maryland Hematology and Oncology Associates Baltimore, Maryland, United States, 21236 United States, Minnesota The Duluth Clinic Duluth, Minnesota, United States, 55805 United States, Tennessee The West Clinic Memphis, Tennessee, United States, 38120 The Sarah Cannon Research Center Nashville, Tennessee, United States, 37203 United States, Texas Presbyterian Hospital Dallas, Texas, United States, 75231 United States, Washington Multicare Health System Tacoma, Washington, United States, 98405 收起 <<
NCT00087997	Soft Tissue Sarcoma	Phase 2	Completed	-	-
NCT00522834	Melanoma	Phase 3	Terminated	-	-

Elesclomol/伊利司莫参考文献

[1]Foy JP, Bazire L, et al. A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes. BMC Med. 2017;15(1):165.

[2]Kirshner JR, He S, et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther. 2008 Aug;7(8):2319-27.

Elesclomol/伊利司莫实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.50mL

0.50mL

0.25mL

12.48mL

2.50mL

1.25mL

24.97mL

4.99mL

2.50mL

Elesclomol/伊利司莫技术信息

CAS号	488832-69-5
分子式	C₁₉H₂₀N₄O₂S₂
分子量	400.52
SMILES Code	O=C(NN(C)C(C1=CC=CC=C1)=S)CC(NN(C)C(C2=CC=CC=C2)=S)=O
MDL No.	MFCD12911784

别名	伊利司莫(STA-4783) ;STA-4783
运输	蓝冰
InChI Key	BKJIXTWSNXCKJH-UHFFFAOYSA-N
Pubchem ID	300471

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Keep in dark place, sealed in dry, store in freezer, under -20°C

动物实验配方

5% DMSO+40%PEG300+5%Tween80 +50%water 10 mg/mL

大规格询价

* 公司或机构名称：

* 姓名：

* 电话：

* 邮箱： * 国家/区域： * 需求量：

* 货号：

* CAS号：

* 产品名称：在线留言：

请填写此表格索取QC报告。我们很快就会发送到您的邮箱。您的信息在我们这里是安全的。*是必填项.

产品名称： * 货号：

* 姓名：

* 电话：

* 邮箱： * 公司或机构名称： * 部门：留言给我们：

摩尔计算器

计算溶液所需的质量，体积或浓度。 Ambeed 摩尔浓度计算器基于以下方程式：

浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)=质量 (g)

浓度

体积

分子量

质量

*在制备母液时，请始终参考产品标签或 MSDS / COA（在产品页面可下载）上所显示的对应批次产品的分子量。

靶点

靶点	数值

总药量计算器

动物实验：给药剂量 mg/kg 动物体重 g 动物数量只每天给药次给药天

需要的总药量： mg

工作液计算器

动物实验：给药剂量 mg/kg 动物体重 g 给药体积 μL

您需要配制的工作液浓度为：mg/mL

细胞研究

细胞系	浓度	检测类型	检测时间	活性说明	数据源

647-V cell	Growth inhibition assay	Inhibition of human 647-V cell growth in a cell viability assay, IC50=6.9 nM	SANGER
697 cell	Growth inhibition assay	Inhibition of human 697 cell growth in a cell viability assay, IC50=6.13 nM	SANGER
A2780 cell	Growth inhibition assay	Inhibition of human A2780 cell growth in a cell viability assay, IC50=0.594 nM	SANGER
A375 cell	Growth inhibition assay	Inhibition of human A375 cell growth in a cell viability assay, IC50=4.14 nM	SANGER
A427 cell	Growth inhibition assay	Inhibition of human A427 cell growth in a cell viability assay, IC50=6.07 nM	SANGER
A549 cell	Growth inhibition assay	Inhibition of human A549 cell growth in a cell viability assay, IC50=19.6 nM	SANGER
A673 cell	Growth inhibition assay	Inhibition of human A673 cell growth in a cell viability assay, IC50=11.6 nM	SANGER
A704 cell	Growth inhibition assay	Inhibition of human A704 cell growth in a cell viability assay, IC50=27.45 nM	SANGER
ABC-1 cell	Growth inhibition assay	Inhibition of human ABC-1 cell growth in a cell viability assay, IC50=0.365 nM	SANGER
AGS cell	Growth inhibition assay	Inhibition of human AGS cell growth in a cell viability assay, IC50=2.86 nM	SANGER
BCPAP cell	Growth inhibition assay	Inhibition of human BCPAP cell growth in a cell viability assay, IC50=1.34 nM	SANGER
BHT-101 cell	Growth inhibition assay	Inhibition of human BHT-101 cell growth in a cell viability assay, IC50=3.72 nM	SANGER
BV-173 cell	Growth inhibition assay	Inhibition of human BV-173 cell growth in a cell viability assay, IC50=5.39 nM	SANGER
C-33-A cell	Growth inhibition assay	Inhibition of human C-33-A cell growth in a cell viability assay, IC50=7.58 nM	SANGER
Ca9-22 cell	Growth inhibition assay	Inhibition of human Ca9-22 cell growth in a cell viability assay, IC50=4.25 nM	SANGER
CAL-51 cell	Growth inhibition assay	Inhibition of human CAL-51 cell growth in a cell viability assay, IC50=0.126 nM	SANGER
CAL-72 cell	Growth inhibition assay	Inhibition of human CAL-72 cell growth in a cell viability assay, IC50=3.02 nM	SANGER
CHL-1 cell	Growth inhibition assay	Inhibition of human CHL-1 cell growth in a cell viability assay, IC50=2.81 nM	SANGER
CHP-212 cell	Growth inhibition assay	Inhibition of human CHP-212 cell growth in a cell viability assay, IC50=7.34 nM	SANGER
COLO-684 cell	Growth inhibition assay	Inhibition of human COLO-684 cell growth in a cell viability assay, IC50=9.21 nM	SANGER
COR-L105 cell	Growth inhibition assay	Inhibition of human COR-L105 cell growth in a cell viability assay, IC50=6.76 nM	SANGER
DMS-273 cell	Growth inhibition assay	Inhibition of human DMS-273 cell growth in a cell viability assay, IC50=7.06 nM	SANGER
ES1 cell	Growth inhibition assay	Inhibition of human ES1 cell growth in a cell viability assay, IC50=0.749 nM	SANGER
ES3 cell	Growth inhibition assay	Inhibition of human ES3 cell growth in a cell viability assay, IC50=5.79 nM	SANGER
ES4 cell	Growth inhibition assay	Inhibition of human ES4 cell growth in a cell viability assay, IC50=4.39 nM	SANGER
ES7 cell	Growth inhibition assay	Inhibition of human ES7 cell growth in a cell viability assay, IC50=3.59 nM	SANGER
ES8 cell	Growth inhibition assay	Inhibition of human ES8 cell growth in a cell viability assay, IC50=1.32 nM	SANGER
EW-1 cell	Growth inhibition assay	Inhibition of human EW-1 cell growth in a cell viability assay, IC50=5.24 nM	SANGER
EW-11 cell	Growth inhibition assay	Inhibition of human EW-11 cell growth in a cell viability assay, IC50=4.9 nM	SANGER
EW-16 cell	Growth inhibition assay	Inhibition of human EW-16 cell growth in a cell viability assay, IC50=1.61 nM	SANGER
EW-24 cell	Growth inhibition assay	Inhibition of human EW-24 cell growth in a cell viability assay, IC50=3.83 nM	SANGER
F-36P cells	Proliferation assay	Antiproliferative activity against human F-36P cells, IC50=0.28 μM	21341675
FADU cell	Growth inhibition assay	Inhibition of human FADU cell growth in a cell viability assay, IC50=5.66 nM	SANGER
G-401 cell	Growth inhibition assay	Inhibition of human G-401 cell growth in a cell viability assay, IC50=5.43 nM	SANGER
GAMG cell	Growth inhibition assay	Inhibition of human GAMG cell growth in a cell viability assay, IC50=2.51 nM	SANGER
GB-1 cell	Growth inhibition assay	Inhibition of human GB-1 cell growth in a cell viability assay, IC50=6.71 nM	SANGER
HCE-T cell	Growth inhibition assay	Inhibition of human HCE-T cell growth in a cell viability assay, IC50=4.45 nM	SANGER
HD-MY-Z cell	Growth inhibition assay	Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50=5.91 nM	SANGER
HEL cell	Growth inhibition assay	Inhibition of human HEL cell growth in a cell viability assay, IC50=7.08 nM	SANGER
H-EMC-SS cell	Growth inhibition assay	Inhibition of human H-EMC-SS cell growth in a cell viability assay, IC50=3.68 nM	SANGER
HOS cell	Growth inhibition assay	Inhibition of human HOS cell growth in a cell viability assay, IC50=2.53 nM	SANGER
HSC-3 cell	Growth inhibition assay	Inhibition of human HSC-3 cell growth in a cell viability assay, IC50=3.02 nM	SANGER
HSC-4 cell	Growth inhibition assay	Inhibition of human HSC-4 cell growth in a cell viability assay, IC50=4.8 nM	SANGER
HT-1080 cell	Growth inhibition assay	Inhibition of human HT-1080 cell growth in a cell viability assay, IC50=4.99 nM	SANGER
HuCCT1 cell	Growth inhibition assay	Inhibition of human HuCCT1 cell growth in a cell viability assay, IC50=5.52 nM	SANGER
human H4 cell	Growth inhibition assay	Inhibition of human H4 cell growth in a cell viability assay, IC50=7.25 nM	SANGER
human JAR cell	Growth inhibition assay	Inhibition of human JAR cell growth in a cell viability assay, IC50=5.97 nM	SANGER
human K5 cell	Growth inhibition assay	Inhibition of human K5 cell growth in a cell viability assay, IC50=7 nM	SANGER
human KU-19-19 cell	Growth inhibition assay	Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50=7.09 nM	SANGER
human NB14 cell	Growth inhibition assay	Inhibition of human NB14 cell growth in a cell viability assay, IC50=6.64 nM	SANGER
human SW982 cell	Growth inhibition assay	Inhibition of human SW982 cell growth in a cell viability assay, IC50=7.44 nM	SANGER
human T47D cell	Growth inhibition assay	Inhibition of human T47D cell growth in a cell viability assay, IC50=16.79 nM	SANGER
HUTU-80 cell	Growth inhibition assay	Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=0.791 nM	SANGER
K562 cells	Proliferation assay	Antiproliferative activity against human K562 cells, IC50=18 μM	21341675
KOSC-2 cell	Growth inhibition assay	Inhibition of human KOSC-2 cell growth in a cell viability assay, IC50=5.45 nM	SANGER
KP-4 cell	Growth inhibition assay	Inhibition of human KP-4 cell growth in a cell viability assay, IC50=2.17 nM	SANGER
MCF7 cell	Growth inhibition assay	Inhibition of human MCF7 cell growth in a cell viability assay, IC50=31.36 nM	SANGER
MC-IXC cell	Growth inhibition assay	Inhibition of human MC-IXC cell growth in a cell viability assay, IC50=7.17 nM	SANGER
MDA-MB-157 cell	Growth inhibition assay	Inhibition of human MDA-MB-157 cell growth in a cell viability assay, IC50=2.92 nM	SANGER
MES-SA/Dx5 cells	Cytotoxicity assay	Cytotoxicity against human MES-SA/Dx5 cells, IC50=5 nM	23937981
MHH-ES-1 cell	Growth inhibition assay	Inhibition of human MHH-ES-1 cell growth in a cell viability assay, IC50=5.69 nM	SANGER
MOLT-16 cell	Growth inhibition assay	Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=4.53 nM	SANGER
NB69 cell	Growth inhibition assay	Inhibition of human NB69 cell growth in a cell viability assay, IC50=1.22 nM	SANGER
NBsusSR cell	Growth inhibition assay	Inhibition of human NBsusSR cell growth in a cell viability assay, IC50=3.13 nM	SANGER
NCI-H1563 cell	Growth inhibition assay	Inhibition of human NCI-H1563 cell growth in a cell viability assay, IC50=4.13 nM	SANGER
NCI-H1703 cell	Growth inhibition assay	Inhibition of human NCI-H1703 cell growth in a cell viability assay, IC50=3.68 nM	SANGER
NCI-H292 cell	Growth inhibition assay	Inhibition of human NCI-H292 cell growth in a cell viability assay, IC50=0.886 nM	SANGER
NCI-SNU-1 cell	Growth inhibition assay	Inhibition of human NCI-SNU-1 cell growth in a cell viability assay, IC50=4.86 nM	SANGER
NOS-1 cell	Growth inhibition assay	Inhibition of human NOS-1 cell growth in a cell viability assay, 3.66e-05 μM	SANGER
NUGC-3 cell	Growth inhibition assay	Inhibition of human NUGC-3 cell growth in a cell viability assay, IC50=7.33 nM	SANGER
OCI-AML2 cells	Proliferation assay	Antiproliferative activity against human OCI-AML2 cells, IC50=0.35 μM	21341675
OVCAR-3 cell	Growth inhibition assay	Inhibition of human OVCAR-3 cell growth in a cell viability assay, IC50=6.2 nM	SANGER
OVCAR-4 cell	Growth inhibition assay	Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=5.87 nM	SANGER
OVCAR-5 cell	Growth inhibition assay	Inhibition of human OVCAR-5 cell growth in a cell viability assay, IC50=1.83 nM	SANGER
OVCAR-8 cell	Growth inhibition assay	Inhibition of human OVCAR-8 cell growth in a cell viability assay, IC50=3.99 nM	SANGER
PC-14 cell	Growth inhibition assay	Inhibition of human PC-14 cell growth in a cell viability assay, IC50=24.73 nM	SANGER
PC-3 cell	Growth inhibition assay	Inhibition of human PC-3 cell growth in a cell viability assay, IC50=7.89 nM	SANGER
PC3 cells	Function assay	Inhibition of PDK1-mediated AKT phosphorylation at Thr308 residue in human PC3 cells by ELISA, IC50=0.113 μM	21341675
PSN1 cell	Growth inhibition assay	Inhibition of human PSN1 cell growth in a cell viability assay, IC50=3.84 nM	SANGER
SF126 cell	Growth inhibition assay	Inhibition of human SF126 cell growth in a cell viability assay, IC50=1.95 nM	SANGER
SK-OV-3 cell	Growth inhibition assay	Inhibition of human SK-OV-3 cell growth in a cell viability assay, IC50=3.75 nM	SANGER
SNU-387 cell	Growth inhibition assay	Inhibition of human SNU-387 cell growth in a cell viability assay, IC50=9.49 nM	SANGER
SW1710 cell	Growth inhibition assay	Inhibition of human SW1710 cell growth in a cell viability assay, IC50=5.16 nM	SANGER
SW1990 cell	Growth inhibition assay	Inhibition of human SW1990 cell growth in a cell viability assay, IC50=4.32 nM	SANGER
SW756 cell	Growth inhibition assay	Inhibition of human SW756 cell growth in a cell viability assay, IC50=4.13 nM	SANGER
T-24 cell	Growth inhibition assay	Inhibition of human T-24 cell growth in a cell viability assay, IC50=1.55 nM	SANGER
TE-8 cell	Growth inhibition assay	Inhibition of human TE-8 cell growth in a cell viability assay, IC50=5.41 nM	SANGER
U251 cell	Growth inhibition assay	Inhibition of human U251 cell growth in a cell viability assay, IC50=9.86 nM	SANGER
UM-UC-3 cell	Growth inhibition assay	Inhibition of human UM-UC-3 cell growth in a cell viability assay, IC50=7.06 nM	SANGER

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT00088088	Stage IIIB Non-Small Cell Lung... 展开 >> Cancer Stage IV Non-Small Cell Lung Cancer 收起 <<	Phase 1 Phase 2	Completed	-	United States, Arkansas ... 展开 >> NEA Clinic Jonesboro, Arkansas, United States, 72401 United States, California Wilshire Oncology Medical Group Pamona, California, United States, 91767 St. Francis Memorial Hospital San Francisco, California, United States Cancer Institute Medical Group Santa Monica, California, United States, 90404 Kaiser Permanete Vallejo, California, United States United States, Connecticut Oncology Associates of Bridgeport Trumball, Connecticut, United States, 06611 United States, Florida ACORN Miami, Florida, United States Oncology Hematology Consultants Sarasota, Florida, United States, 34236 United States, Illinois University of Chicago Chicago, Illinois, United States, 60637 The Cancer Institute at Alexian Brothers Elk Grove Village, Illinois, United States, 60007 Ingalls Hospital Harvey, Illinois, United States, 60426 United States, Louisiana Overton Brooks, VAMC Shreveport, Louisiana, United States, 71101 LSUHSC - Shreveport Feist Weiller Cancer Center Shreveport, Louisiana, United States, 71130 United States, Maryland Maryland Hematology and Oncology Associates Baltimore, Maryland, United States, 21236 United States, Minnesota The Duluth Clinic Duluth, Minnesota, United States, 55805 United States, Tennessee The West Clinic Memphis, Tennessee, United States, 38120 The Sarah Cannon Research Center Nashville, Tennessee, United States, 37203 United States, Texas Presbyterian Hospital Dallas, Texas, United States, 75231 United States, Washington Multicare Health System Tacoma, Washington, United States, 98405 收起 <<
NCT00087997	Soft Tissue Sarcoma	Phase 2	Completed	-	-
NCT00522834	Melanoma	Phase 3	Terminated	-	-
NCT00088114	Neoplasms	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Beth Israel-Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT00827203	Metastatic Solid Tumors	Phase 1	Suspended	January 2011	United States, Maryland ... 展开 >> Mayo Clinic Rochester, Maryland, United States, 55905 United States, Texas University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development San Antonio, Texas, United States, 78229 United States, Wisconsin University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 收起 <<
NCT00888615	Fallopian Tube Clear Cell Aden... 展开 >>ocarcinoma Fallopian Tube Endometrioid Adenocarcinoma Fallopian Tube Mucinous Adenocarcinoma Fallopian Tube Serous Adenocarcinoma Fallopian Tube Transitional Cell Carcinoma Ovarian Brenner Tumor Ovarian Clear Cell Adenocarcinoma Ovarian Endometrioid Adenocarcinoma Ovarian Mucinous Adenocarcinoma Ovarian Seromucinous Carcinoma Ovarian Serous Adenocarcinoma Ovarian Transitional Cell Tumor Primary Peritoneal Serous Adenocarcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Undifferentiated Fallopian Tube Carcinoma Undifferentiated Ovarian Carcinoma 收起 <<	Phase 2	Active, not recruiting	-	-
NCT00084214	Melanoma	Phase 1 Phase 2	Completed	-	-
NCT01280786	Acute Myeloid Leukemia	Phase 1	Unknown	August 2014	Canada, Ontario ... 展开 >> Princess Margaret Hospital Toronto, Ontario, Canada, MSG 2M9 收起 <<
NCT00808418	Prostate Cancer	Phase 1	Completed	-	United States, California ... 展开 >> Pacific Coast Hematology/Oncology Medical Group Fountain Valley, California, United States, 92708 United States, Maryland Mayo Clinic Rochester, Maryland, United States, 55905 United States, North Dakota Mid Dakota Clinic Bismarck, North Dakota, United States, 58501 United States, Texas University of Texas Health Science Center, Cancer Therapy & Research Center, Institute for Drug Development San Antonio, Texas, United States, 78229 United States, Wisconsin University of Wisconsin Paul P. Carbone Comprehensive Cancer Center Madison, Wisconsin, United States, 53792 收起 <<

Elesclomol/伊利司莫 {[allProObj[0].p_purity_real_show]}

Elesclomol/伊利司莫纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Elesclomol/伊利司莫质控信息

Elesclomol/伊利司莫生物活性

Elesclomol/伊利司莫细胞研究

Elesclomol/伊利司莫临床研究

Elesclomol/伊利司莫参考文献

Elesclomol/伊利司莫实验方案

Elesclomol/伊利司莫技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Elesclomol/伊利司莫 {[allProObj[0].p_purity_real_show]}

Elesclomol/伊利司莫 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Elesclomol/伊利司莫 质控信息

Elesclomol/伊利司莫 生物活性

Elesclomol/伊利司莫 细胞研究

Elesclomol/伊利司莫 临床研究

Elesclomol/伊利司莫 参考文献

Elesclomol/伊利司莫 实验方案

Elesclomol/伊利司莫 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Elesclomol/伊利司莫纯度/质量文件产品仅供科研

Elesclomol/伊利司莫质控信息

Elesclomol/伊利司莫生物活性

Elesclomol/伊利司莫细胞研究

Elesclomol/伊利司莫临床研究

Elesclomol/伊利司莫参考文献

Elesclomol/伊利司莫实验方案

Elesclomol/伊利司莫技术信息